Background: The use of statins has increased substantially over the last 2 decades in England
| INTRODUCTION
During the last 2 decades, compelling clinical evidence has emerged for the use of statins in the primary and secondary prevention of cardiovascular events. [1] [2] [3] [4] The clinical effectiveness, safety profile, and long duration of action that allows single daily dosing have all resulted in a substantial increase in the use of statins in England. 5 Studies have
shown that the use of statins has increased since their introduction in 1990s, but this use varies considerably across the different European markets, with the highest use in the United Kingdom and lowest in
France. [6] [7] [8] [9] In the United Kingdom, statins dominate the lipid-lowering market and accounted for more than 90% of the overall expenditure on lipid-lowering medicines in 2004 representing the largest annual drug cost to the National Health System (NHS) at £738 million. 5, 10 This has had a significant budget impact on the UK NHS.
The combination of the pivotal Scandinavian Simvastatin
Survival Study 1 and the Heart Protection Study 11 and the patent expiry of UK branded simvastatin in 2003 12 led the National
Institute for Health and Clinical Excellence (NICE) guidelines to recommend using statins for secondary prevention (post-myocardial infarction) and in primary prevention of cardiovascular diseases for adults with ≤20% ten-year risk using the Framingham risk score. 13 Studies have shown that rosuvastatin is more potent than atorvastatin, which is, in turn, more potent than simvastatin in reducing total cholesterol, low-density lipoprotein-cholesterol, and triglycerides. [14] [15] [16] [17] [18] Intensive lipid lowering with potent statins (eg, atorvastatin) has demonstrated beneficial effects in lowering mortality and morbidity after acute coronary syndrome, post-myocardial infarction, and coronary atherosclerosis. [19] [20] [21] Since the patent expiry of branded simvastatin (Zocor) in 2003, branded statins faced increasing competition from less expensive generic versions of these medicines. Generic statins were expected to continue to dominate this market since they were considered first-line treatment for hyperlipidaemia when used as monotherapy. 22 A number of studies have suggested the overall increase in statin use may be due to a number of different factors including population ageing, health authority programmes, outcome of clinical trials, guidelines, and pharmaceutical industry marketing. 9, [23] [24] [25] 
| Statistical analysis
Segmented regression analysis of interrupted time series data was used to examine the effects of the major changes in use of the statins market leaders' simvastatin, atorvastatin, and the more potent agent rosuvastatin using the method of Wagner et al. 34 The effect was assessed by 2 parameters, level (β 2 and β 4 ) and trend (β 3 and β 5 ). The following segmented regression analysis equation was applied to each individual study outcome measure: 
KEY POINTS
• Simvastatin and atorvastatin were the most commonly prescribed statins since 1998.
• Statins had a significant budget impact on the UK national health system.
• Generic simvastatin and atorvastatin have reduced overall expenditure on these medicines in England.
• Following patent expiry, when costs are low, potency appears to influence prescribing choice.
• Prescribers tend to respond to patent expiry by prescribing generically, ahead of national guidance. Average strength per prescription for each statin was calculated by using the following formula:
Average strength ¼ ∑ Number of prescriptions of each strength×Strength of prescription ð Þ Number of prescriptions :
Paired t test was used to compare the mean average strength between branded and generic statins where P < .05 was considered statistically significant. All calculations were performed using Microsoft Excel 2013 and STATA MP 13 3 | RESULTS Table 2 shows that the prices of branded simvastatin (Zocor), branded rosuvastatin (Crestor), branded cerivastatin (Lipobay), and branded fluvastatin (Lescol) were not changed significantly during the study period, which gave a relatively flat pricing structure regardless of dose.
| Statins prices
Generic simvastatin, atorvastatin, fluvastatin, and pravastatin prices gradually decreased since their introduction. In contrast, branded atorvastatin (Lipitor) and branded pravastatin (Lipostat) 40 mg prices reduced sharply from 2003, thereafter, prices reduced gradually.
| Expenditure of statins in primary care
Primary care expenditure on statins increased steadily by 125% during (Table 3) .
| Post-generic simvastatin market phase (2003-2011)
The change in trend (β 3 ) showed a significant increase in use of generic simvastatin (Table 3) Zocor as a result of the very low volume of use at that period (Table 3 and Figure 3 ). Table 4 shows the average strength of statins prescribed by year since 1998. The annual average strengths of prescribed simvastatin increased following the introduction of generic simvastatin. The annual average strengths of prescribed generic simvastatin were significantly higher than branded simvastatin (P < .005). Similarly, the annual average strengths of prescribed atorvastatin increased following the introduction of generic atorvastatin, and the annual strengths of generic atorvastatin were significantly higher than branded atorvastatin (P < .05). The annual average strengths of Crestor have remained stable since its introduction (Table 4) .
| DISCUSSION
Expenditure on statins has been a significant contributor to the increasing burden on the NHS budget exceeding £600 million in
2004. The main drivers of increased expenditure were as follows: (1) increased use of statins overall between 1998 and 2015 ( Figures 1   and 2 ) and (2) use of more expensive branded agents (Zocor, Lipitor, and Crestor) ( Figure 2 ). Increased statins use has been reported in many studies across Europe, Australia, and China in recent years. 6, [35] [36] [37] [38] This increase was attributed to the aggressive use of statins for primary and secondary prevention of coronary heart disease. [39] [40] [41] The impact of branded statins on expenditure in our study is similar to the findings from a Swedish study. 42 The price of generic simvastatin fell sharply during the study period as a result of the competition between generic manufacturers. This was in line with the work of Cook et al describing the large number of competitors producing generics after the patent expiry of 11 out of 13 blockbuster agents just 2 months after patent expiry. 43 The availability of less expensive generic simvastatin reduced expenditure as it replaced branded simvastatin ( Table 2 During the pre-generic phase, when prices were similar, the annual growth of branded atorvastatin (the more potent agent) exceeded branded simvastatin, suggesting that prescribing decisions were based on potency ( Figure 3 and Table 3 ). In the post-generic simvastatin market phase, the availability of the less expensive generic simvastatin reduced the use trend of all strengths of Zocor and low doses Lipitor (Table 3) . Internationally, financial incentives result in governments promoting prescribing of medicines by international non-proprietary name to encourage use of generics. [44] [45] [46] [47] [48] In England, NICE guidance recommended prescribing statins with the lowest acquisition cost and the availability of the lower price generic simvastatin compared to other statins, resulted in the complete substitution of branded simvastatin, and to a lesser extent, low dose of branded atorvastatin with generic simvastatin (Figure 2 ). This reflects the findings from use studies of statins in Scotland and Sweden where simvastatin had most market share (63% and 83%, respectively). 35, 42 The growth in use of generic simvastatin 40 mg ( Figure 3 and Figure 2 ). This suggests that the prescribing decisions during this phase were based on price rather than potency. Interestingly, the growth of high-dose branded atorvastatin (40 and 80 mg) also increased (Table 3) . as the price of these doses reduced ( Table 2 ). Despite the fact that rosuvastatin was more potent than other statins, 49 with a modestly lower price than branded atorvastatin, its use was limited (Figure 2 ). This implies that either cost reduction was not sufficient or that the perceived lack of safety data on long-term use inhibited prescribers. Table 3 ). This result was also in line with revised NICE guideline CG 181 (in 2014) 31 that recommended the use of atorvastatin in primary and secondary prevention of cardiovascular diseases and key clinical trials, IDEAL, 51 TNT, 52 and PROVE-IT-TIMI22, 53 that all identified an effect of high-dose atorvastatin in secondary care prevention. Similarly, to generic simvastatin, the use of generic atorvastatin started to increase before the publication of this guidance. This suggests that when price was not a factor, potency was influencing prescribing decisions ( Figure 2) .
Interestingly, the segmented regression analysis also showed that with the availability of generic versions of statins, the use of higher doses increased. Before 2003, Zocor 20 mg had the highest annual growth, but with the availability of generic simvastatin, 40-mg doses had the highest growth (Table 3 ). This is confirmed in Table 4 that shows the average strength of statins prescribed following the marketing of generic simvastatin and atorvastatin increased significantly. This elevation of the average strength of prescribed statins indicates that higher doses with increased potency were chosen. This finding reinforces the hypothesis that potency and unit cost were the key influencing factors for choosing statins.
The strengths of this study were that we were able to analyse use of statins over a long period, which allowed analysis by Interrupted Time Series. We were able to access actual amounts of statins prescribed in primary care that was then converted into DDDs, which avoid the inherent problems when accessing data in DDDs. A potential limitation was that data were derived from prescriptions dispensed rather than prescriptions written so can take no account of prescriptions obtained by a patient but never presented for dispensing-which is one crude measure of adherence.
| CONCLUSION
In England, the availability of generic simvastatin and atorvastatin has reduced overall expenditure on statins significantly. This study has shown that when there is a significant price difference, acquisition cost appears to be the main influencing factor in the use of statins, but, when costs are similar, potency is the key factor. Furthermore, when less expensive generic statins became available, prescribers used higher doses, presumably to elicit the extra clinical benefit. This suggests that English prescribers are cost sensitive and appear to be prepared to trade marginal benefit for savings.
FUNDING
This research was not funded or sponsored by any organisation, and the researchers are independent of any funding bodies.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
PRIOR POSTING AND PRESENTATIONS
An abstract of part of this study was accepted for presentation for the 
